- Home
- / Chimeric Therapeutics
Chimeric Therapeutics
Stock Price
$0
2024-10-04
Market Capitalization
$12.7 M
2024-10-04
Revenue
$4 M
FY, 2025
Chimeric Therapeutics Summary
Company Summary
- Overview
- Chimeric Therapeutics is a clinical-stage cell therapy company. It offers NK and T cell-derived allogeneic therapies, clinical trials, and other services for solid tumors.
- Type
- Public
- Status
- Active
- Founded
- 2020
- HQ
- Carlton, AU | view all locations
- Cybersecurity rating
- Sectors
Table of Contents
LocationsView all
1 location detected
Carlton, VIC HQ
Australia
Level 3/62 Lygon St
Chimeric Therapeutics Financials
Summary Financials
- Gross profit (H1, 2026)
- $2.5M
- Net income (H1, 2026)
- ($11.2M)
- Cash (H1, 2026)
- $2.5M
- EBIT (H1, 2026)
- ($11.2M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026